TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01100619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: dosed with capsules daily
Study: NCT03824769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Maintenance + Healthy Thinking
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance Treatment + Future Thinking
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
Study: NCT02260687

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT03714204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique
Description: The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
Study: NCT03774251

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection
Description: The patient will undergo a single platelet-rich plasma peritendinous injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
Study: NCT01246934

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: ASR METHOD
Study: NCT01313689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physicians' Choice
Description: Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
Study: NCT01959022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin XL
Description: Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
Study: NCT02991131

Intervention type: DRUG
Intervention: Tedizolid (Sivextro, BAY1192631)
Description: Antibiotic

Intervention type: DRUG
Intervention: Linezolid
Description: Antibiotic
Study: NCT01337115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB plus CFNB
Description: A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFNB
Description: A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
Study: NCT04160767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Vivomixx
Description: VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free diet
Description: Gluten free diet will be encouraged in both arms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: Gluten free diet will be encouraged in both arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
Study: NCT03369990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A(DWP450)
Study: NCT05087004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Council
Description: Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
Study: NCT02368587

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: WJMSCs Vs. placebo
Description: WJMSCs Vs. placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WJMSCs Vs. placebo
Study: NCT04184089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (15 L/m)
Description: nasal cannula at a flow rate of 15 l/min and FiO2 of 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (30 L/m)
Description: nasal cannula at a flow rate of 30l/min and FiO2 of 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (60 L/m)
Description: nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
Study: NCT01560663

Intervention type: DRUG
Intervention: Docetaxel- Carboplatin
Description: Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
Study: NCT01458392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Subcutaneous dose of dalantercept once every 3 weeks.
Study: NCT01597804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infection Prophylaxis and Management
Description: Undergo preoperative preparation with the Bathing Bundle
Study: NCT04698863

Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: eveluating oxygen reserve in blood

Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: eveluating oxygen reserve in blood
Study: NCT01697670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with Gliolan
Description: Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
Study: NCT01744262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Anesthesia
Description: Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
Study: NCT03369990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline
Study: NCT03772444

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
Study: NCT00609765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Every 28 Days: Avastin 5mg/kg iv days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozocin
Description: Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Premedication: Dexamethasone 20mg intravenously days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Premedication: Ondansetron 16mg intravenously days 1-5
Study: NCT01943409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: soybean oil-based lipid emulsion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: olive oil-based lipid emulsion
Study: NCT03631160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAES treatmen
Description: In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TAES treatmen
Description: Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output .
Study: NCT02783521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling sessions
Description: During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List Control
Description: After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
Study: NCT02733393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion (SPG) Block
Description: Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study: NCT03841682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CARE2
Description: I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity.
Study: NCT04960735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOICE intervention
Description: The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Model construction: Based on the process mapping and on root cause analysis, the multidisciplinary team designs the new care pathway. Professionals are trained in those tasks allocated according to the new care process.
Study: NCT02874274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visit Program (HVP)
Description: The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
Study: NCT01745848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Study: NCT02012114

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cysteamine bitartrate
Description: No intervention
Study: NCT03226275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol-Amlodipine FDC
Description: Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol-Amlodipine FDC
Description: Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
Study: NCT00478543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study: NCT03520855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game
Description: DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETP
Description: Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ETP
Description: Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses.
Study: NCT03898739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction from different angles
Description: Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction from different angles
Description: Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction from different angles
Description: Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
Study: NCT03833505

Intervention type: OTHER
Intervention: Bitestrip
Description: The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.

Intervention type: OTHER
Intervention: Bitestrip
Description: The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
Study: NCT04273776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 10 mg
Description: 10 mg of suvorexant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5 mg of zolpidem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Avicel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Avicel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Avicel